

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No. L24230MH1990PLC058071.

PART -1				Rs. In Lakhs			
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2015							
Sl. No.		Particulars	Quarter Ended			Year Ended	
			31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
			Audited	Unaudited	Audited	Audited	Audited
1	(a) Net Sales/Income from Operations		447.46	525.48	628.78	1867.79	2070.43
	(b) Other Operating Income		0.00	0.00	0.00	12.88	11.63
	Total Income From Operations (Net)		447.46	525.48	628.78	1880.67	2082.06
2	Expenses						
	a. Cost of Materials Consumed		185.92	225.64	382.96	913.34	1213.97
	b. Purchase of Stock in Trade		0.00	0.00	0.00	0.00	0.00
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade		-2.69	62.97	55.91	-1.33	154.36
	d. Employee Benfit Expenses		121.00	108.30	92.03	408.36	370.28
	e. Depreciation and Amortisation Expense		31.01	31.54	30.79	131.23	116.72
	f. Loss/Gain on Foreign Exchange Transactions		0.00	0.00	0.00	-0.34	0.00
	g. Other expenditure		78.63	87.54	120.99	376.94	437.87
	Total Expenses		413.86	515.99	682.68	1828.20	2293.20
3	Profit from operations before Other Income and Fiance Cost (1-2)		33.59	9.49	-53.90	52.47	-211.14
4	Other Income		0.06	0.16	2.10	2.03	0.00
5	Profit before Fiinance Costs (3+4)		33.65	9.65	-51.80	54.50	-211.14
6	Finance Costs		13.69	14.42	10.69	53.81	44.52
7	Profit/ Loss before Tax (5-6)		19.96	-4.77	-62.49	0.69	-255.66
8	Tax Expense		0.00	0.00	110.37	105.04	-110.37
9	Net profit (+)/Loss (-) for the period (7-8)		19.96	-4.77	47.88	-104.35	-145.29
10	Paid-up equity share capital (Face Value of Rs. 10/- each)		992.58	992.58	992.58	992.58	992.58
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year					-463.48	
12	Earnings Per Share (EPS) - Face Value of Share Rs. 10/ each (Not Annualised)		0.00	0.00	0.00	0.00	0.00
	- Basic and diluted		0.20	-0.05	0.48	-1.04	-1.45

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No.L24230MH1990PLC058071.


PART -II							
Select Information for the Quarter Ended 31.03.2015							
Sl. No.	Particulars	Quarter Ended 31.03.2015	Quarter Ended 31.12.2014	Quarter Ended 31.03.2014	Twelve Months ended 31.12.2015	Twelve Months ended 31.12.2014	Previous accounting year ended 31.03.2015
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	-No. of shares	2450100	2450100	2450100	2450100	2450100	2450100
	-Percentage of shareholding	24.48	24.48	24.48	24.48	24.48	24.48
2	Promoters and promoter group Shareholding						
a)	Pledged/Encumbered						
	-No. of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a% of the total share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered						
	-No. of shares	7556900	7556900	7556900	7556900	7556900	7556900
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00	100
	- Percentage of shares (as a% of the total share capital of the Company)	75.52	75.52	75.52	75.52	75.52	75.52

PARTICULARS	Quarter Ended 31.03.2015
B. INVESTORS COMPLAINTS	
Pending at the beginning of the Quarter	Nil
Received during the quarter	03
Disposed off during the quarter	03
Remaining unresolved at the end of the quarter	Nil

Notes:

- 1) The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 29.05.2015. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 31.03.2015
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited



Vimal D Shah
Managing Director

Date: 29.05.2015
Place: Ankleshwar

STATEMENT OF ASSETS AND LIABILITIES		
	31.03.2015 (Audited)	31.03.2014 (Audited)
1. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	-463.48	-357.77
(2) Share Application money pending allotment		
(2) Non - Current Liabilities		
(a) Long Term borrowings	748.93	733.93
(b) Long Term provisions		
(3) Current Liabilities		
(a) Short Term borrowings	67.32	18.68
(b) Trade payables	279.16	565.87
© Other current liabilities	98.01	109.61
(d) Short Term provisions	92.84	69.65
TOTAL	1815.35	2132.54
II. ASSETS		
(1) Non -current assets		
(a) Fixed Assets		
(i) Tangible assets	861.06	906.53
(ii) Capital Work in Progress		
(b) Non Current investments	0.86	0.89
© Deferred tax assets (net)	122.03	227.06
(d) Long Term Loans and Advances	132.40	129.45
(2) Current Assets		
(a) Current investments		
(b) Inventories	250.03	277.68
© Trade Receivables	376.51	517.79
(d) Cash & cash equivalents	20.00	31.01
(e) Short Term Loans and advances	52.46	42.13
(f) Other Current assets		
	1815.35	2132.54

For Norris Medicines Limited



Vimal D Shah
Managing Director

Date: 29.05.2015
Place: Ankleshwar